Bleakley Financial Group LLC Buys New Position in NRx Pharmaceuticals, Inc. $NRXP

Bleakley Financial Group LLC bought a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 117,204 shares of the company’s stock, valued at approximately $318,000.

Several other hedge funds have also modified their holdings of the stock. Anson Funds Management LP grew its stake in NRx Pharmaceuticals by 26.2% during the 3rd quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock valued at $6,683,000 after purchasing an additional 420,129 shares in the last quarter. Vanguard Group Inc. grew its stake in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. AdvisorShares Investments LLC grew its stake in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after purchasing an additional 78,339 shares in the last quarter. Geode Capital Management LLC grew its stake in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares in the last quarter. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NRXP has been the subject of a number of recent analyst reports. Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. D. Boral Capital restated a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Ascendiant Capital Markets raised their price objective on NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, BTIG Research restated a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, NRx Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $38.25.

NRx Pharmaceuticals Stock Down 0.5%

NASDAQ:NRXP opened at $4.42 on Friday. The business’s 50 day moving average is $2.78 and its two-hundred day moving average is $2.37. NRx Pharmaceuticals, Inc. has a 52 week low of $1.62 and a 52 week high of $4.59. The company has a market cap of $160.14 million, a PE ratio of -4.06 and a beta of 2.02.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $19.43 million. As a group, sell-side analysts expect that NRx Pharmaceuticals, Inc. will post -0.3 EPS for the current fiscal year.

NRx Pharmaceuticals News Roundup

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $45 price objective, and still sees long-term earnings growth for NRx Pharmaceuticals, with estimates remaining strongly positive in later years.
• Neutral Sentiment: The analyst continued to model a path to profitability over time, including estimated EPS of $0.67 for FY2027, $2.49 for FY2028, and $4.51 for FY2029, suggesting long-term upside potential if execution improves.
• Negative Sentiment: HC Wainwright cut its earnings estimates for multiple periods, including FY2026 to ($0.23) EPS from $0.13, FY2027 to $0.67 from $1.23, FY2028 to $2.49 from $3.18, FY2029 to $4.51 from $5.06, and FY2030 to $5.76 from $6.15, which likely weighs on sentiment.
• Negative Sentiment: Near-term quarterly forecasts were also reduced, including Q2 2026 to ($0.05), Q3 2026 to ($0.06), Q4 2026 to ($0.07), Q1 2027 to $0.00, Q2 2027 to $0.09, Q3 2027 to $0.21, and Q4 2027 to $0.36, signaling slower expected progress before profitability scales.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.